- \n
- Largest purchase amount and longest duration purchase to-date<\/i><\/li>\n
- Four tonne per month order secured <\/i><\/li>\n
- Order follows five successful OxC-betaTM<\/sup> Livestock commercial trials conducted with various species over the past six months<\/i><\/li>\n<\/ul>\n
OTTAWA, Ontario–(BUSINESS WIRE<\/a>)–
\nAvivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (\u201cAvivagen\u201d), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that Meyenberg International Group, Avivagen\u2019s consultant in Mexico, has entered into a contract which secures a four tonne per month recurring order forOxC-beta\u2122 Livestock in Mexico.\n<\/p>\n\nThe contract, which is 18 months from signing and includes an order for 500 Kgs delivered April 30th<\/sup>, is a commitment to purchase a minimum<\/i> of four tonnes monthly, commencing in July, 2021 and ending October, 2022\n<\/p>\n
\n\u201cAs we continue to see successful commercial trials conclude in those jurisdictions where OxC-beta\u2122 Livestock is approved, we anticipate increased demand to follow, as has recently been demonstrated in Mexico and Thailand,\u201d said Kym Anthony, Chief Executive Officer of Avivagen. \u201cWith numerous other commercial trials currently underway and nearing completion, it is our belief that the continued success of such company conducted trials will help to accelerate the adoption and use of OxC-beta\u2122 Livestock in approved jurisdictions and beyond. It is our belief that OxC-beta\u2122 Livestock, once started by a customer, becomes core to their continued operations and will drive recurring orders for years to come.\u201d\n<\/p>\n
Meyenberg International Group
\n
<\/b>With a client base across North America and a well-earned reputation for enabling rapid growth for clients expanding into LATAM, Meyenberg\u2019s experience in Mexico has enabled Avivagen to quickly establish and grow sales in the country since securing regulatory approval in August 2019.\n<\/p>\nAbout OxC-beta\u2122 Technology and OxC-beta\u2122 Livestock
\n
<\/b>Avivagen\u2019s OxC-beta\u2122 technology is derived from Avivagen discoveries about \u03b2-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta\u2122 Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia and Malaysia.\n<\/p>\n\nAvivagen\u2019s OxC-beta\u2122 Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta\u2122 Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.\n<\/p>\n
About Avivagen
\n
<\/b>Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com<\/a>. The contents of the website are expressly not incorporated by reference in this press release.\n<\/p>\nForward Looking Statements
\n
<\/b>This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions \u201caim\u201d, \u201canticipate\u201d, \u201cappear\u201d, \u201cbelieve\u201d, \u201cconsider\u201d, \u201ccould\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cif\u201d, \u201cintend\u201d, \u201cgoal\u201d, \u201chope\u201d, \u201clikely\u201d, \u201cmay\u201d, \u201cplan\u201d, \u201cpossibly\u201d, \u201cpotentially\u201d, \u201cpursue\u201d, \u201cseem\u201d, \u201cshould\u201d, \u201cwhether\u201d, \u201cwill\u201d, \u201cwould\u201d and similar expressions. Statements set out in this news release relating to the recurring nature of the orders under the contract described above, the anticipated date of fulfillment for the order described, Avivagen\u2019s expectation that the customer in question will live up to its contractual commitment to purchase product monthly, anticipated increase in demand for Avivagen\u2019s products, Avivagen\u2019s expectation that commercial trials currently underway will be completed and yield positive results, the anticipated impact of the results of such trials on demand for product, expectations as to the recurring and long term nature of a customer\u2019s purchases once they begin using Avivagen\u2019s products and the possibility for OxC-beta\u2122 Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the order described may not result in new orders for Avivagen\u2019s products, the customer plans may change due to many reasons, timing of fulfillment of the order may be delayed beyond current expectation for a number of reasons which would push fulfillment and recognition of revenues for this order into a future quarter or cause such order to be cancelled, the parties to the contract described may not live up to their contractual commitments and\/or may agree to amend such contract to reduce the commitments described above, demand for Avivagen\u2019s products may not continue to grow and could decline, commercial trials may not be completed and, if completed, may not yield results that are positive or which lead to additional demand for Avivagen\u2019s products, except as otherwise stated, customers are under no obligation to continue using Avivagen\u2019s products and Avivagen\u2019s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications, including human applications, and may not be widely accepted as a replacement for antibiotics in livestock feeds, , in each case due to many factors, many of which are outside of Avivagen\u2019s control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen\u2019s most recent management\u2019s discussion and analysis of financial condition available at www.SEDAR.com<\/a>. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.<\/i><\/p>\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/i><\/p>\n
\nCopyright \u00a9 2021 Avivagen Inc. OxC-beta\u2122 is a trademark of Avivagen Inc\n<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210503005224\/en\/<\/a><\/span><\/p>\n
\nAvivagen Inc.
\n
Drew Basek
\n
Director of Investor Relations
\n
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
\n
Phone: 416-540-0733
\n
E-mail: d.basek@avivagen.com<\/a><\/p>\n\nKym Anthony
\n
Chief Executive Officer
\n
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
\n
Head Office Phone: 613-949-8164
\n
Website: www.avivagen.com<\/a><\/p>\nKEYWORDS:<\/b> North America Canada<\/p>\n
INDUSTRY KEYWORDS:<\/b> Biotechnology Agriculture Health Natural Resources<\/p>\n
MEDIA:<\/b><\/p>\n
\n","protected":false},"excerpt":{"rendered":"
Avivagen Announces Recurring Order for OxC-betaTM Livestock Largest purchase amount and longest duration purchase to-date Four tonne per month order secured Order follows five successful OxC-betaTM Livestock commercial trials conducted with various species over the past six months OTTAWA, Ontario–(BUSINESS WIRE)– Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (\u201cAvivagen\u201d), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that Meyenberg International Group, Avivagen\u2019s consultant in Mexico, has entered into a contract which secures a four tonne per month recurring order forOxC-beta\u2122 Livestock in Mexico. The contract, which is 18 months from signing and includes an order … <\/p>\n
- Four tonne per month order secured <\/i><\/li>\n